Phase 2 N=6 Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)
Alternating Hemiplegia of Childhood
Primary: Time Duration of AHC Episodes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy
Hereditary Spastic Paraplegia · Adrenomyeloneuropathy
Primary: Change From Baseline Walking Time in 10 Meter Walk Test to the Measurement Taken Directly After rTMS — -5.41; 1.70 seconds
N/A N=20 Perinatal Stroke: Understanding Brain Reorganization
Stroke · Hemiparesis
Primary: Cortical Excitability MEP Amplitude (µV) — 325 µV
Phase 3 N=63 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Cerebral Palsy, Dyskinetic
Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…
N/A N=83 Intensive Unimanual (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegia
Cerebral Palsy · Hemiplegia · Children
Primary: Jebsen-Taylor Test of Hand Function — 323.6; 479.5; 265.6; 121.3 seconds
N/A N=20 Brain Stimulation and Hand Training in Children With Hemiparesis
Pediatric Hemiparesis
Primary: Change in Assisting Hand Assessment (AHA) — 6.4; 8; 5.5; 7.6 score on a scale
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=10 Pediatric Teleneuromodulation
Cerebral Palsy (CP)
Primary: Status/Safety Assessment — 4; 7; 20; 12 number of sessions symptom reported
N/A N=15 Use of Joystick-operated Ride-on-toys to Improve Affected Arm Use and Function in Children With Hemiplegic Cerebral Palsy
Hemiplegic Cerebral Palsy
Primary: Change in Affected Arm Movement Control — 74.9; 78.3; 83.8 percentage
Phase 3 N=212 Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Primary: Mean Change From Baseline to TC 1, Week 6 in MAS Score in the TC 1 PTMG — -1.5; -1.9; -2.2 score on a scale — p=0.0118
Phase 2 N=27 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Atypical Hemolytic-Uremic Syndrome
Primary: Proportion of Patients With Complete TMA Response — 63.6 Percentage of Participants
Early Phase 1 N=11 Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis
Hemiparesis
Primary: Adverse Events/Safety Assessment. — 0; 0; 0; 0 Participants
Phase 2 N=91 A Study of UCB and MSCs in Children With CP: ACCeNT-CP
Cerebral Palsy
Primary: Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change — 5.83; 4.27; 3.15 score on a scale
Phase 2 N=134 Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington Disease
Primary: Number of Patients With at Least One Adverse Event — 119 Participants
N/A N=15 Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy
Cerebral Palsy
Primary: Change in Assisting Hands Assessment Logit Score at End of Treatment — 2.63; 4.33 Scores on a scale
Phase 1 N=24 AC220 for Children With Relapsed/Refractory ALL or AML
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
N/A N=48 A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Hypophosphatasia (HPP)
Primary: Survival — 270.5 days
N/A N=44 Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy
Cerebral Palsy · Hemiplegia · Children
Primary: Change in Score on Assisting Hand Assessment (AHA) — 0.42; 0.56 score — p=<0.01
Phase 3 N=69 Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP) — 2.00 scores on a scale
Phase 3 N=67 A Trial of Levodopa in Angelman Syndrome
Angelman Syndrome
Primary: Bayley Cognitive Age Equivalent at 1 Year — 19; 19 months — p=0.75
N/A N=20 Single-session tDCS in Cerebral Palsy
Cerebral Palsy · Perinatal Stroke · Periventricular Leukomalacia
Primary: Change in Motor Evoked Potential Amplitude — 12.4; 81.7; -34.4 percent change
N/A N=39 Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
N/A N=9 Therapeutic Dance Intervention for Children With Cerebral Palsy
Cerebral Palsy
Primary: Congruent Trial (Hearts) Accuracy — 87.96; 87.50 percentage of correct
N/A N=5 Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
Dystonia
Primary: Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale — 14.7 change in points on a scale
Phase 3 N=65 Hyper- and Hypokalemic Periodic Paralysis Study
Hyperkalemic Periodic Paralysis · Hypokalemic Periodic Paralysis
Primary: HYP Attack Rate — 0.9; 4.8 attacks per week
N/A N=29 Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
Amyotrophic Lateral Sclerosis (ALS) · Neuromuscular Diseases
Primary: Percent Change in Maximal Inspiratory Pressure (MIP) — 0.3; -3.1; -4.8; -5.0 percentage change in MIP from baseline
Phase 3 N=25 Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
Atypical Hemolytic Uremic
Primary: Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response — 64.0 percentage of participants
N/A N=32 Therapeutic Effects of Constraint-Induced Movement Therapy on Young Children With Cerebral Palsy
Cerebral Palsy Spastic Hemiplegic
Primary: Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test — 0.83; 0.00; 0.50; -0.05 score on a scale
Phase 2 N=6 Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
Pseudohypoparathyroidism Type 1a · Albright Hereditary Osteodystrophy
Primary: Change in Urine cAMP — 3048 fm/uL
Phase 3 N=12 Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy
Cerebral Palsy
Primary: Oxygen Consumption (ml/kg/Min) — 14.82; 16.75; 28.77 ml/kg/min